


Financial highlights

The Sawai Group adopted International Financial Reporting Standards (IFRS) in the preparation of its consolidated financial statements in fiscal 2017.


Revenue / Core operating profit



In recent years, the Sawai Group has achieved rapid growth with the success of upfront investment in production facilities and personnel in anticipation of expanding demand for generic drugs. In fiscal 2020, the Group recorded all-time high revenue despite the impact of a reduced number of medical consultations and other factors due to the spread of COVID-19.

Note: Fiscal years 2011 through 2016 show figures for revenue based on Japanese-GAAP.


Profit attributable to owners of the Company / Return on equity



In a challenging environment for both the Japan business and the U.S. business, the Group worked to secure profits by aggressively reducing raw material and other costs. The decrease in fiscal 2020 was mainly due to impairment loss on manufacturing and marketing approval rights for Tosymra™ acquired through the U.S. business in 2019.

Note: Fiscal years 2011 through 2016 show figures for profit attributable to owners of parent and return on equity based on Japanese-GAAP.


R&D expenses



The Sawai Group invested aggressively in research and development in order to be first to market with new products that will differentiate us from our competitors to achieve future growth. In fiscal 2020, R&D expenses were ¥13,883 million, up 7.7% year on year.

Note: Fiscal years 2011 through 2016 show figures for R&D expenses based on Japanese-GAAP.

Dividends per share / Dividend payout ratio




We aim to pay stable and continuous dividends with a target payout ratio of 30%, taking account of the balance between investment for growth and dividends, as well as comprehensively considering the consolidated financial results for each fiscal year, the dividend payout ratio, and other measures aimed at shareholder returns. In fiscal 2020, the Company provided an annual return to shareholders of ¥130 per share.

Note: As the Company implemented a two-for-one stock split of its common shares on October 1, 2013, figures for fiscal 2011 through fiscal 2013 were recalculated to reflect this split.

Non-financial highlights


Scope of data: Sawai Pharmaceutical Co., Ltd.

Number of GMP audits conducted by Sawai Pharmaceutical




Sawai Pharmaceutical has formed a dedicated audit team, which performs more than 100 GMP audits a year. The number of audits conducted each fiscal year fluctuates within a certain range as the year for the next audit is determined based on the results of the previous audit. In fiscal 2020, the number of audits conducted declined temporarily due to the impact of the COVID-19 pandemic. However, we plan to implement remote audits and third party audits (outsourcing) going forward.

Sales volume / Production capacity




The Group's ability to supply a large number of top quality generic drugs is backed by our industry-leading production capacity. We are also able to adjust production in accordance with supply and demand due to the high proportion of in-house manufacturing.

Number of patents held



We own a variety of patents, including a patent for reducing the bitterness of active ingredients and a patent for orally dissolving (OD) tablets that can be taken without water. Recently, there has been an increase in the number of patent applications for unique Sawai formulation technologies that are not linked to specific active ingredients.

Amount of reduction in medical expenses



The Sawai Group's greatest contribution to society lies in increasing the sustainability of the health insurance system by reducing the burden of medical expenses through the supply of generic drugs. We have contributed to reducing medical expenses by approximately ¥300.0 billion.